Oxford, UK – May 9, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced expanded access to Axumin® (fluciclovine (18F)) in Europe. The first commercial production of Axumin in Belgium occurred recently, with the first Belgian patients being dosed. This follows the first administration of Axumin in Luxembourg earlier this year. Axumin is the first and only PET imaging agent approved in the European Union for use in in men with suspected recurrent prostate cancer. Axumin is commercially available in Belgium, Luxembourg, Italy, France, Norway, the Czech Republic, The Netherlands, United Kingdom and Austria with further European countries set to follow soon.

For further information please visit http://www.blueearthdiagnostics.com/blue-earth-diagnostics-continues-to-expand-access-to-axumin-fluciclovine-18f-in-europe/